Iris BioTechnologies (fka IRSB)

[albundy]

hmmm, so after checking their site, it looks like they posted 3 updates yesterday, all relating to the "building blocks" that were utilized in the study that was published in Nature.com (link back). These "building blocks" were used to produce a new variation of a chemotherapeutic drug that, compared to the previous version, "led to increased therapeutic activity of the drug in vivo" by having "induced tumor regression". In addition, the new variation (NT4-paclitaxel) "...is very hydrophilic, which may improve its pharmacokinetic profile and allow the use of less toxic dilution buffers, further decreasing its general chemotherapic toxicity."

- 2015-12-02Canalin and Canavanine : New Fmoc building blocks for novel peptides and protein analogs - http://www.iris-biotech.de/news/canalin-and-canavanine-new-fmoc-building-blocks-for-novel-peptides-and-protein-analogs

- Click Chemistry Tools: Propargyl Amino Acids - http://www.iris-biotech.de/news/click-chemistry-tools-propargyl-amino-acids

- Siderophore Building Block: New Hydroxamate-Ornithine for Fmoc/tBu SPPS - http://www.iris-biotech.de/news/siderophore-building-block-new-hydroxamate-ornithine-for-fmoc-tbu-spps